SCHEMBL710750

SCHEMBL710750

O=C(O)CCCCCCc1cccc2ccccc12

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.59
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
MAPT P10636 1/20 0.56
RXFP1 Q9HBX9 1/20 0.56
CYP1A2 P05177 2/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C19 P33261 1/20 0.53
FFAR1 O14842 1/20 0.52
AKR1B1 P15121 1/20 0.52
F13A1 P00488 3/20 0.51
MCL1 Q07820 2/20 0.51
MTNR1A P48039 1/20 0.50
MC4R P32245 1/20 0.49
MC5R P33032 1/20 0.49
MC3R P41968 1/20 0.49
MC1R Q01726 1/20 0.49
SLC16A3 O15427 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6842066 1.00 TDP1 (0.59) TDP1MEN1KMT2AMAPTRXFP1
SCHEMBL29865501 1.00 TDP1 (0.59) TDP1MEN1KMT2AMAPTRXFP1
SCHEMBL29865603 1.00 TDP1 (0.59) TDP1MEN1KMT2AMAPTRXFP1
SCHEMBL11414169 1.00 TDP1 (0.59) TDP1MEN1KMT2AMAPTRXFP1
SCHEMBL1616841 1.00 TDP1 (0.59) TDP1MEN1KMT2AMAPTRXFP1
SCHEMBL3732554 1.00 TDP1 (0.59) TDP1MEN1KMT2AMAPTRXFP1
SCHEMBL6472349 0.98 TDP1 (0.57) TDP1MEN1KMT2AMAPTRXFP1
SCHEMBL27632418 0.98 TDP1 (0.57) TDP1MEN1KMT2AMAPTRXFP1
SCHEMBL6472220 0.98 TDP1 (0.57) TDP1MEN1KMT2AMAPTRXFP1
SCHEMBL22129565 0.98 TDP1 (0.61) TDP1MEN1KMT2AMAPTRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005033067-A1 SALT OF 1,2,6,7,8,8A-HEXAHYDRO-β,δ,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (βR,δ R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE BIOCON LIMITED (IN) 2005-04-14 WO claimed
WO-2005019155-A1 PROCESS FOR THE PREPARATION OF 1,2,6,7,8,8A-HEXAHYDRO-BETA,DELTA,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (BETA R,DELTA R,1S,2S,6S,8S,8AR)-1-NAPHTHALENEHEPTANOIC ACID, SODIUM SALT. BIOCON LIMITED (IN) 2005-03-03 WO claimed
US-11897918-B2 Compositions and methods to increase production Seqirus UK Limited (GB) 2024-02-13 US disclosed
CN-106471119-B Compositions and methods for increasing yield 思齐乐 2020-11-10 CN disclosed
EP-3131578-B1 COMPOSITIONS AND METHODS TO INCREASE PRODUCTION SEQIRUS UK LTD (GB) 2020-06-03 EP disclosed
US-20200040040-A1 COMPOSITIONS AND METHODS TO INCREASE PRODUCTION NOVARTIS (CH) 2020-02-06 US disclosed
US-20190106592-A1 HYPERBRANCHED POLYMERS FOR ORGANIC PIGMENT DISPERSIONS AND WATER-SENSITIVE PIGMENTS BASF COATINGS GMBH (DE) 2019-04-11 US disclosed
CN-106471119-A Compositions and methods for increasing yield 诺华股份有限公司 2017-03-01 CN disclosed
EP-3131578-A1 COMPOSITIONS AND METHODS TO INCREASE PRODUCTION Novartis AG (CH) 2017-02-22 EP disclosed
US-20170044216-A1 COMPOSITIONS AND METHODS TO INCREASE PRODUCTION Seqirus UK Limited (GB) 2017-02-16 US disclosed
US-9353218-B2 Kit for multifunctional compounds forming crosslinked biomaterials ANGIOTECH PHARMACEUTICALS, INC. 2016-05-31 US disclosed
WO-2002096347-A2 METERING AND PACKAGING OF CONTROLLED RELEASE MEDICATION MICRODOSE TECHNOLOGIES, INC. (US) 2002-12-05 WO disclosed
WO-2002087556-A2 PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY ATHEROGENICS, INC. (US) 2002-11-07 WO disclosed
US-6441029-B1 D-.GAMMA.-TOCOTRIENOL, 2-DESMETHYLTOCOTRIENOL, D-.DELTA.-TOCOTRIENOL OR D-TOCOTRIENOL AND LOVASTATIN WISCONSIN ALUMNI RESEARCH FOUNDATION 2002-08-27 US disclosed
US-20020016364-A1 Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality CRABTREE ACQUISITION CO, LLC 2002-02-07 US disclosed
US-20020004521-A1 Use of HMG-COA reductase inhibitors to prevent and treat BPH WEISMAN KENNETH (US) 2002-01-10 US disclosed
WO-2001077072-A2 COMPOUNDS AND METHODS TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY ATHEROGENICS, INC. (US) 2001-10-18 WO disclosed
US-6133312-A ORALLY ADMINISTERING A SYNERGISTIC TOCOTRIENOL AND IONONE MIXTURE TO INHIBIT TUMOR GROWTH WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2000-10-17 US disclosed
EP-0986383-A1 METHOD OF SUPPRESSING TUMOR GROWTH WITH COMBINATIONS OF ISOPRENOIDS AND STATINS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2000-03-22 EP disclosed
WO-1998038993-A1 METHOD OF SUPPRESSING TUMOR GROWTH WITH COMBINATIONS OF ISOPRENOIDS AND STATINS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106592-A1 HYPERBRANCHED POLYMERS FOR ORGANIC PIGMENT DISPERSIONS AND WATER-SENSITIVE PIGMENTS TYR, PAH, AHR TDP1 888/4885MEN1 2875/4885KMT2A 970/4885
US-20170044216-A1 COMPOSITIONS AND METHODS TO INCREASE PRODUCTION MRPL21, CHLSN, MAX TDP1 3386/4885MEN1 3222/4885KMT2A 4670/4885
US-20200040040-A1 COMPOSITIONS AND METHODS TO INCREASE PRODUCTION MRPL21, CHLSN, MAX TDP1 3386/4885MEN1 3222/4885KMT2A 4670/4885
US-11897918-B2 Compositions and methods to increase production MRPL21, CHLSN, MAX TDP1 3386/4885MEN1 3222/4885KMT2A 4670/4885
US-20020016364-A1 Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality HDLBP, CETP, APOB TDP1 2635/4885MEN1 3946/4885KMT2A 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.